Evotec Investor Day Presentation Deck
evotec
Focus
on ...
Focus
on ...
PAGE 65
Drug screening
Target
Molecular disease profiles are driving a paradigm shift
Disease relevance is paramount: 54% of phase 3 trials fail due to inadequate efficacy¹
Disease
relevance
Drug
optimization
Efficacy
IND enabling
Current paradigm: Target driven / Low probability of success / 12 to 15 years
Drug
likeness
Safety
Confirmatory
safety
Clinical
development
Disease relevance
Confirmatory
disease relevance
Future paradigm: Molecular profile driven / Higher probability of success / 8 to 12 years
1) Fogel DB. Factors associated with clinical trials that fail and opportunities for improving the likelihood of success: A review. Contemp Clin Trials Commun. 2018;11:156-164.
Published 2018 Aug 7. doi:10.1016/j.conctc. 2018.08.001.
Market
One drugs
fits all
Right drug,
right patient,
right doseView entire presentation